JP2021527712A5 - - Google Patents
Info
- Publication number
- JP2021527712A5 JP2021527712A5 JP2021519529A JP2021519529A JP2021527712A5 JP 2021527712 A5 JP2021527712 A5 JP 2021527712A5 JP 2021519529 A JP2021519529 A JP 2021519529A JP 2021519529 A JP2021519529 A JP 2021519529A JP 2021527712 A5 JP2021527712 A5 JP 2021527712A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- pabra
- blocker
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685244P | 2018-06-14 | 2018-06-14 | |
| US62/685,244 | 2018-06-14 | ||
| US201862686654P | 2018-06-18 | 2018-06-18 | |
| US62/686,654 | 2018-06-18 | ||
| US201962825619P | 2019-03-28 | 2019-03-28 | |
| US62/825,619 | 2019-03-28 | ||
| PCT/US2019/037371 WO2019241744A1 (en) | 2018-06-14 | 2019-06-14 | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527712A JP2021527712A (ja) | 2021-10-14 |
| JP2021527712A5 true JP2021527712A5 (enExample) | 2022-06-08 |
Family
ID=68842373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519529A Pending JP2021527712A (ja) | 2018-06-14 | 2019-06-14 | 神経系疾患および障害を、診断、監視、および治療するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210251559A1 (enExample) |
| EP (1) | EP3806957A4 (enExample) |
| JP (1) | JP2021527712A (enExample) |
| AU (1) | AU2019287779A1 (enExample) |
| CA (1) | CA3100697A1 (enExample) |
| WO (1) | WO2019241744A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11607395B2 (en) * | 2019-12-18 | 2023-03-21 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| JP7734700B2 (ja) * | 2020-06-04 | 2025-09-05 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニストの形態及び組成物 |
| JP2023541379A (ja) * | 2020-09-01 | 2023-10-02 | キュラセン セラピューティクス インコーポレイテッド | 神経系の疾患及び障害を改善するための組成物及び方法 |
| US12616667B2 (en) | 2021-11-15 | 2026-05-05 | Curasen Therapeutics, Inc. | Compositions and methods for improving neurological diseases and disorders |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| CN120583945A (zh) | 2023-01-20 | 2025-09-02 | 阿托基公司 | 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂 |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
| US9492114B2 (en) * | 2004-06-18 | 2016-11-15 | Banner Health Systems, Inc. | Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease |
| US8758723B2 (en) * | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
| US20100216805A1 (en) * | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| ES2716865T3 (es) * | 2011-02-18 | 2019-06-17 | Scripps Research Inst | Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante |
| US9320724B2 (en) * | 2013-02-13 | 2016-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor |
| WO2014152529A2 (en) * | 2013-03-14 | 2014-09-25 | Georgetown University | Fmri biomarker of neurodegenerative disease |
| US9889087B2 (en) * | 2014-06-10 | 2018-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor |
| WO2017011746A1 (en) * | 2015-07-15 | 2017-01-19 | Adm Diagnostics, Llc | System and methods for determining a brain condition of a patient sybject to multiple disease states |
-
2019
- 2019-06-14 EP EP19819482.1A patent/EP3806957A4/en not_active Withdrawn
- 2019-06-14 CA CA3100697A patent/CA3100697A1/en active Pending
- 2019-06-14 JP JP2021519529A patent/JP2021527712A/ja active Pending
- 2019-06-14 WO PCT/US2019/037371 patent/WO2019241744A1/en not_active Ceased
- 2019-06-14 US US16/972,985 patent/US20210251559A1/en not_active Abandoned
- 2019-06-14 AU AU2019287779A patent/AU2019287779A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023507408A5 (enExample) | ||
| JP2021527711A5 (enExample) | ||
| Chien et al. | Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808 | |
| KR101581289B1 (ko) | 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민 | |
| Vendette et al. | Brain perfusion anomalies in rapid eye movement sleep behavior disorder with mild cognitive impairment | |
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| JP2011093924A (ja) | （−）−ベンラファキシン誘導体並びにその製造方法および使用方法 | |
| JP2024009274A (ja) | Ｒ－ケタミンおよびその塩の医薬品としての応用 | |
| US20180092896A1 (en) | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with a-beta peptide aggregation | |
| Messa et al. | Differential distribution of striatal [123I] β-CIT in Parkinson’s disease and progressive supranuclear palsy, evaluated with single-photon emission tomography | |
| JP2021505575A (ja) | 非ラセミ混合物およびその使用 | |
| EP1904066B1 (en) | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, for treating MENOPAUSE, perimenopause AND COGNITIVE DISORDERS | |
| Hesse et al. | Is correction for age necessary in neuroimaging studies of the central serotonin transporter? | |
| US10071107B2 (en) | Pharmaceutical composition for prevention, treatment or delay of Alzheimer's disease or dementia containing G protein-coupled receptor 19 agent as active ingredient | |
| JP2023541379A5 (enExample) | ||
| Kang et al. | Investigating the effects of noise-induced hearing loss on serotonin transporters in rat brain using 4-[18F]-ADAM/small animal PET | |
| Ma et al. | Validation of 4-[18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography | |
| MX2008000249A (es) | Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos. | |
| Battistin et al. | Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine | |
| Schreckenberger et al. | ” Ecstasy”-induced changes of cerebral glucose metabolism and their correlation to acute psychopathology: An 18-FDG PET Study | |
| Ahn et al. | Preclinical evaluation of [18F] FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson’s disease: pharmacokinetic and efficacy analysis | |
| JP2019529502A5 (enExample) | ||
| KR20260073353A (ko) | 수면 방추 결핍 관련 장애를 치료하기 위한 gaba 수용체 조절제 | |
| TW201922296A (zh) | ［ｆ］ｔ８０７衍生物的製備及用途 | |
| Nyberg | P. 1. c. 051 Predictive modeling–impact of varying doses and different formulations on receptor occupancy profile for quetiapine |